Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies
A Prat, A Chaudhury, N Solovieff, L Paré… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE The prognostic and predictive value of intrinsic subtypes in hormone receptor–
positive, human epidermal growth factor receptor 2–negative advanced breast cancer …
positive, human epidermal growth factor receptor 2–negative advanced breast cancer …
[PDF][PDF] Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− …
Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant
progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 …
progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 …
Prognostic value of intrinsic subtypes in hormone receptor–positive metastatic breast cancer treated with letrozole with or without lapatinib
Importance The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human
epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in …
epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in …
Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre-or perimenopausal patients with hormone receptor positive/human …
Abstract Background: MONALEESA-7 (NCT02278120), the first large randomized phase III
clinical trial dedicated to investigating a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus …
clinical trial dedicated to investigating a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus …
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer …
DJ Slamon, P Neven, S Chia, PA Fasching… - Journal of Clinical …, 2018 - ascopubs.org
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone
receptor–positive/human epidermal growth factor receptor 2–negative advanced breast …
receptor–positive/human epidermal growth factor receptor 2–negative advanced breast …
[HTML][HTML] Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast …
DJ Slamon, P Neven, S Chia, G Jerusalem… - Annals of oncology, 2021 - Elsevier
Background Ribociclib plus fulvestrant demonstrated significant progression-free survival
(PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human …
(PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human …
Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer …
YS Lu, EIBM Mahidin, H Azim, Y ERALP, YS Yap… - Cancer …, 2023 - aacrjournals.org
Background: Combination chemotherapy (CT) remains a standard of care in advanced
breast cancer (ABC) with aggressive disease features (rapidly progressing or highly …
breast cancer (ABC) with aggressive disease features (rapidly progressing or highly …
[HTML][HTML] Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
A Di Leo, J O'Shaughnessy, GW Sledge Jr… - NPJ Breast …, 2018 - nature.com
CDK4 & 6 inhibitors have enhanced the effectiveness of endocrine therapy (ET) in patients
with advanced breast cancer (ABC). This paper presents exploratory analyses examining …
with advanced breast cancer (ABC). This paper presents exploratory analyses examining …
[HTML][HTML] HER2-low status does not affect survival outcomes of patients with metastatic breast cancer (MBC) undergoing first-line treatment with endocrine therapy plus …
F Carlino, A Diana, A Ventriglia, A Piccolo, C Mocerino… - Cancers, 2022 - mdpi.com
Simple Summary Breast cancers (BCs) with a HER2 immunohistochemical score of 1+ or 2+
with negative in situ hybridization are referred as HER2-low BCs. The knowledge about the …
with negative in situ hybridization are referred as HER2-low BCs. The knowledge about the …
The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy …
GW Sledge, M Toi, P Neven, J Sohn, K Inoue… - JAMA …, 2020 - jamanetwork.com
Importance Statistically significant overall survival (OS) benefits of CDK4 and CDK6
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 …
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 …